Claim 30% Off TipRanks
New trading tool for TEM bullsTempus AI, Inc. Class A ( (TEM) ) has provided an announcement.
Tempus AI, Inc., a technology company applying artificial intelligence to precision medicine, reported robust growth for the quarter and year ended December 31, 2025, with 2025 revenue up 83.4% year over year to $1.27 billion. The business is anchored by diagnostics, including oncology and hereditary testing, and a data and applications segment that licenses insights from its expansive multimodal dataset.
For the fourth quarter of 2025, Tempus posted revenue of $367.2 million, an 83.0% increase, with diagnostics revenue more than doubling and data and applications up 25.1%, while gross profit rose 94.7% to $237.7 million. The company narrowed its losses on an adjusted basis, achieving positive fourth-quarter Adjusted EBITDA of $12.9 million and improving full-year Adjusted EBITDA to a loss of $7.4 million, supported by strong remaining contract value of over $1.1 billion and net revenue retention of 126%.
Tempus ended 2025 with $759.7 million in cash and marketable securities and issued 2026 guidance calling for approximately $1.59 billion in revenue and Adjusted EBITDA of about $65 million, signaling a path toward higher-margin growth. Operationally, it launched Paige Predict, an AI-powered digital pathology suite, reported study results showing its Immune Profile Score better predicts immunotherapy outcomes than conventional biomarkers, and expanded strategic collaborations with NYU Langone Health and Northwestern Medicine to broaden genomic testing access and develop AI-driven diagnostic tools.
The most recent analyst rating on (TEM) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Tempus AI, Inc. Class A stock, see the TEM Stock Forecast page.
Spark’s Take on TEM Stock
According to Spark, TipRanks’ AI Analyst, TEM is a Neutral.
The score is held back primarily by weak profitability, high leverage, and negative operating/free cash flow. Technicals are mixed-to-weak with negative MACD and the stock below key moving averages. These are partly offset by a positive earnings-call outlook highlighting strong operating growth and a milestone of positive adjusted EBITDA with constructive guidance.
To see Spark’s full report on TEM stock, click here.
More about Tempus AI, Inc. Class A
Tempus AI, Inc. is a Chicago-based technology company that applies artificial intelligence to advance precision medicine and patient care. Leveraging one of the world’s largest libraries of multimodal clinical and molecular data and an AI-enabled operating system, it provides diagnostic and data-driven tools to physicians and biopharma partners, with a particular focus on oncology and personalized therapeutics discovery and development.
Average Trading Volume: 4,809,544
Technical Sentiment Signal: Sell
Current Market Cap: $9.99B
Learn more about TEM stock on TipRanks’ Stock Analysis page.